Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Opening Session Panel Discussion

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Peter Clark, MA, MD, FRCP: A Payer Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Varsha Gandhi, PhD, on Ibrutinib

Germline Genetic Variants Associated With CAR T-Cell Therapy Safety and Efficacy in Hematologic Malignancies

FDA Approves SimpleScreen CRC Blood-Based Screening Test for Colorectal Cancer

MMUD vs MRD Transplantation in the Posttransplant Cyclophosphamide Era

Global Breast Cancer Survival Estimates: WHO Analysis

Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer